Payment overview · 2025
General Payments
$95.23
3 reported records · 3 companies
Healthcare provider profile · identity verified
Christopher A. Martin, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · RAINELLE, WV · NPI 1851407142
Verified facts
What the public records show
CMS Open Payments records show Christopher A. Martin, D.O. received $95.23 in general payments during 2025 across 3 reported records.
Abbott Laboratories accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.09 | 50.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.40 | 34.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.74 | 15.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.23 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $48.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.40 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 71 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 249 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 247 | 70 |
| Lisinopril | Lisinopril | 221 | 59 |
| Metformin Hcl | Metformin Hcl | 190 | 47 |
| Furosemide | Furosemide | 182 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 37 |
| Omeprazole | Omeprazole | 145 | 44 |
| Montelukast Sodium | Montelukast Sodium | 126 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 37 |
| Simvastatin | Simvastatin | 118 | 28 |
| Losartan Potassium | Losartan Potassium | 111 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 37 |
| Prednisone | Prednisone | 110 | 69 |
| Carvedilol | Carvedilol | 105 | 25 |
| Eliquis | Apixaban | 95 | 19 |
| Potassium Chloride | Potassium Chloride | 91 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 32 |
| Allopurinol | Allopurinol | 84 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 20 |
| Meloxicam | Meloxicam | 81 | 26 |
| Gabapentin | Gabapentin | 77 | 16 |
| Ezetimibe | Ezetimibe | 73 | 18 |
| Jardiance | Empagliflozin | 71 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 20 |
| Ozempic | Semaglutide | 70 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Sertraline Hcl | Sertraline Hcl | 68 | 18 |
| Alendronate Sodium | Alendronate Sodium | 67 | 15 |
| Famotidine | Famotidine | 62 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 20 |
| Pregabalin | Pregabalin | 60 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 60 | suppressed |
| Celecoxib | Celecoxib | 58 | 18 |
| Finasteride | Finasteride | 57 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 13 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | 11 |
| Cefdinir | Cefdinir | 46 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 22 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 14 |
| Buspirone Hcl | Buspirone Hcl | 37 | 13 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 15 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | 11 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Sulindac | Sulindac | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Topiramate | Topiramate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Veozah | Fezolinetant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.23 · 3 records | Abbott Laboratories | Cologuard Collection Kit, FREESTYLE LIBRE 2, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error